PLIANT THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
PLIANT THERAPEUTICS, INC. (PLRX) reported Increase (Decrease) in Accrued Liabilities of -$2.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $4.42M.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$6.47M.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$1.51M.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$2.03M, a 139.30% decline year-over-year.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was -$12.17M, a 419.60% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $3.81M, a 36.89% increase from fiscal 2023.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $2.78M, a 64.82% decline from fiscal 2022.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $7.90M, a 193.28% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $4.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.05M 10-Q · filed 2026-08-11 | -$3.57M derived: sum of 3 quarters · filed 2026-08-11 | -$5.60M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$6.47M 10-Q · filed 2026-05-11 | -$7.99M derived: sum of 2 quarters · filed 2026-05-11 | -$10.02M derived: sum of 3 quarters · filed 2026-05-11 | -$13.83M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$3.54M derived: sum of 2 quarters · filed 2026-03-11 | -$7.36M derived: sum of 3 quarters · filed 2026-08-11 | -$12.17M 10-K · filed 2026-03-11 | |
| 2025-09-30 | -$2.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$5.84M derived: sum of 2 quarters · filed 2026-08-11 | -$10.65M 10-Q · filed 2025-11-06 | -$16.78M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$3.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$8.62M 10-Q · filed 2026-08-11 | -$14.75M derived: sum of 3 quarters · filed 2026-08-11 | -$9.58M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$4.81M 10-Q · filed 2026-05-11 | -$10.94M derived: sum of 2 quarters · filed 2026-05-11 | -$5.77M derived: sum of 3 quarters · filed 2026-05-11 | -$91.00K derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$6.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$960.00K derived: sum of 2 quarters · filed 2026-03-11 | $4.72M derived: sum of 3 quarters · filed 2026-03-11 | $3.81M 10-K · filed 2026-03-11 | |
| 2024-09-30 | $5.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.85M derived: sum of 2 quarters · filed 2025-11-06 | $9.94M 10-Q · filed 2025-11-06 | $10.63M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $5.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.77M 10-Q · filed 2025-08-07 | $5.47M derived: sum of 3 quarters · filed 2025-08-07 | $2.46M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$910.00K 10-Q · filed 2025-05-08 | -$211.00K derived: sum of 2 quarters · filed 2025-05-08 | -$3.22M derived: sum of 3 quarters · filed 2025-05-08 | $2.41M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $699.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$2.31M derived: sum of 2 quarters · filed 2025-03-03 | $3.32M derived: sum of 3 quarters · filed 2025-03-03 | $2.78M 10-K · filed 2025-03-03 | |
| 2023-09-30 | -$3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.62M derived: sum of 2 quarters · filed 2024-11-07 | $2.08M 10-Q · filed 2024-11-07 | $1.67M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $5.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $5.09M 10-Q · filed 2024-08-07 | $4.68M derived: sum of 3 quarters · filed 2025-03-03 | $7.59M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | -$538.00K 10-Q · filed 2024-05-06 | -$949.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.96M derived: sum of 3 quarters · filed 2025-03-03 | $7.73M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | -$411.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $2.50M derived: sum of 2 quarters · filed 2025-03-03 | $8.27M derived: sum of 3 quarters · filed 2025-03-03 | $7.90M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $2.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $8.68M derived: sum of 2 quarters · filed 2023-11-09 | $8.31M 10-Q · filed 2023-11-09 | $10.29M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $5.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $5.40M 10-Q · filed 2023-08-09 | $7.38M derived: sum of 3 quarters · filed 2024-02-27 | $9.43M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | -$364.00K 10-Q · filed 2023-05-09 | $1.61M derived: sum of 2 quarters · filed 2024-02-27 | $3.66M derived: sum of 3 quarters · filed 2024-02-27 | $4.42M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $4.03M derived: sum of 2 quarters · filed 2024-02-27 | $4.79M derived: sum of 3 quarters · filed 2024-02-27 | $2.69M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $2.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.81M derived: sum of 2 quarters · filed 2022-11-08 | $719.00K 10-Q · filed 2022-11-08 | $2.18M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $759.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$1.33M 10-Q · filed 2022-08-08 | -$1.32M 10-Q · filed 2021-08-09 | $128.00K derived: sum of 3 quarters · filed 2022-08-08 | $107.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$2.09M 10-Q · filed 2022-05-09 | -$631.00K derived: sum of 2 quarters · filed 2022-05-09 | -$652.00K derived: sum of 3 quarters · filed 2022-05-09 | $1.02M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.44M derived: sum of 2 quarters · filed 2022-03-01 | $3.11M derived: sum of 3 quarters · filed 2022-03-01 | $2.69M 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.65M derived: sum of 2 quarters · filed 2021-11-09 | $1.23M 10-Q · filed 2021-11-09 | $3.13M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $1.25M 10-Q · filed 2021-08-09 | $3.15M derived: sum of 3 quarters · filed 2022-03-01 | $3.63M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | -$424.00K 10-Q · filed 2021-05-10 | $1.47M derived: sum of 2 quarters · filed 2022-03-01 | $1.96M derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $2.38M derived: sum of 2 quarters · filed 2022-03-01 | $4.25M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $486.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $2.36M 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | $1.87M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |